TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
belinostat Sensitive: A1 - Approval
|
belinostat Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
pralatrexate Sensitive: A1 - Approval
|
pralatrexate Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
denileukin diftitox Sensitive: A1 - Approval
|
denileukin diftitox Sensitive: A1 - Approval
|
ALK positive
|
Peripheral T-cell Lymphoma
|
ALK positive
|
Peripheral T-cell Lymphoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
cyclophosphamide + etoposide IV Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
bortezomib Sensitive: A2 - Guideline
|
bortezomib Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
bendamustine Sensitive: A2 - Guideline
|
bendamustine Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
lenalidomide Sensitive: A2 - Guideline
|
lenalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
EPOCH Sensitive: A2 - Guideline
|
EPOCH Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
duvelisib Sensitive: A2 - Guideline
|
duvelisib Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
DHAX Sensitive: A2 - Guideline
|
DHAX Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
DHAP Sensitive: A2 - Guideline
|
DHAP Sensitive: A2 - Guideline
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
RP6530 Sensitive: B - Late Trials
|
RP6530 Sensitive: B - Late Trials
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
DZD4205 Sensitive: B - Late Trials
|
DZD4205 Sensitive: B - Late Trials
|
IL2RA expression
|
Peripheral T-cell Lymphoma
|
IL2RA expression
|
Peripheral T-cell Lymphoma
|
denileukin diftitox Sensitive: C1 - Off-label
|
denileukin diftitox Sensitive: C1 - Off-label
|
PD-L1 overexpression
|
Peripheral T-cell Lymphoma
|
PD-L1 overexpression
|
Peripheral T-cell Lymphoma
|
GB226 Sensitive: C3 – Early Trials
|
GB226 Sensitive: C3 – Early Trials
|
PD-1 overexpression
|
Peripheral T-cell Lymphoma
|
PD-1 overexpression
|
Peripheral T-cell Lymphoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
RHOA mutation
|
Peripheral T-cell Lymphoma
|
RHOA mutation
|
Peripheral T-cell Lymphoma
|
copanlisib Sensitive: C3 – Early Trials
|
copanlisib Sensitive: C3 – Early Trials
|
IDH2 mutation
|
Peripheral T-cell Lymphoma
|
IDH2 mutation
|
Peripheral T-cell Lymphoma
|
copanlisib Sensitive: C3 – Early Trials
|
copanlisib Sensitive: C3 – Early Trials
|
TSC2 mutation
|
Peripheral T-cell Lymphoma
|
TSC2 mutation
|
Peripheral T-cell Lymphoma
|
copanlisib Sensitive: C3 – Early Trials
|
copanlisib Sensitive: C3 – Early Trials
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
BV-ICE Sensitive: C3 – Early Trials
|
BV-ICE Sensitive: C3 – Early Trials
|
IL10-H
|
Peripheral T-cell Lymphoma
|
IL10-H
|
Peripheral T-cell Lymphoma
|
CHOP Resistant: C3 – Early Trials
|
CHOP Resistant: C3 – Early Trials
|
RPS6 underexpression
|
Peripheral T-cell Lymphoma
|
RPS6 underexpression
|
Peripheral T-cell Lymphoma
|
ruxolitinib Sensitive: C3 – Early Trials
|
ruxolitinib Sensitive: C3 – Early Trials
|
TNFRSF8 negative
|
Peripheral T-cell Lymphoma
|
TNFRSF8 negative
|
Peripheral T-cell Lymphoma
|
chidamide Sensitive: C3 – Early Trials
|
chidamide Sensitive: C3 – Early Trials
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
CHEP-BV Sensitive: C3 – Early Trials
|
CHEP-BV Sensitive: C3 – Early Trials
|
CXCL12 expression
|
Peripheral T-cell Lymphoma
|
CXCL12 expression
|
Peripheral T-cell Lymphoma
|
tipifarnib Sensitive: C3 – Early Trials
|
tipifarnib Sensitive: C3 – Early Trials
|
TET2 mutation
|
Peripheral T-cell Lymphoma
|
TET2 mutation
|
Peripheral T-cell Lymphoma
|
CHOP Sensitive: C3 – Early Trials
|
CHOP Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
Peripheral T-cell Lymphoma
|
DNMT3A mutation
|
Peripheral T-cell Lymphoma
|
CHOP Resistant: C3 – Early Trials
|
CHOP Resistant: C3 – Early Trials
|
TNFRSF8 negative
|
Peripheral T-cell Lymphoma
|
TNFRSF8 negative
|
Peripheral T-cell Lymphoma
|
rituximab + lenalidomide + brentuximab vedotin Sensitive: C4 – Case Studies
|
rituximab + lenalidomide + brentuximab vedotin Sensitive: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CVAD Resistant: C4 – Case Studies
|
CVAD Resistant: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CEOP-E Resistant: C4 – Case Studies
|
CEOP-E Resistant: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
DICE Resistant: C4 – Case Studies
|
DICE Resistant: C4 – Case Studies
|